P.J. : Ahora toca ver la valoración que hacen los Analistas de esta Nueva Espectativa . Por poner un ejemplo ... los Analistas de RX Securities , hace unas semanas , pusieron en valor a APLIDIN y valoraban que en caso de Aprobarse para Tratar Multiple Myeloma en 3ª y 4ª Linea ... las ventas serían increscendo y superarían los 100 Millones al año para el 2024 y los 170 Millones al año para el 2028 .
**************
PharmaMar starts a quadruple combination study with Aplidin for the treatment of multiple myeloma .
* Aplidin® is an ideal compound for combining with other therapies given its absence of Hematological toxicity, excellent safety profile along with its already demonstrated tolerance in triple combination .
* The success of this study will place Aplidin® at the front line of multiple myeloma treatment .
* The trial looks at combating multiple myeloma with the synergies of different mechanisms of action, increasing the possibility of success.
Madrid, August 9th, 2017 -
PharmaMar (MSE:PHM) announced the start of a multicenter quadruple combination clinical study with Aplidin® (plitidepsina), along with other compounds for the treatment of multiple myeloma.
The main objective of this study is to evaluate the recommended dose (RD), the efficacy of the combination along with the safety profile, evaluating potential response and resistance markers, amongst other parameters.
The above mentioned study will follow the same line in combating multiple myeloma with compounds that have different mechanisms of action to increase the success rate. Aplidin® has already demonstrated, through other studies, its potential in combining with other compounds, due to its lack of hematological toxicity. Given this, Aplidin® can be administered at a maximum dose, with the corresponding increase in efficacy of the therapy. This will put Aplidin® on the first line of multiple myeloma treatment.
...